PT  - JOURNAL ARTICLE
AU  - GRIGORIOS KARAGKIOUZIS
AU  - ELEFTHERIOS SPARTALIS
AU  - DEMETRIOS MORIS
AU  - DEMETRIOS PATSOURAS
AU  - ATHANASIOS ATHANASIOU
AU  - IOANNIS KARATHANASIS
AU  - ALEXIOS VERVENIOTIS
AU  - FROSO KONSTANTINOU
AU  - ILIAS A. KOUERINIS
AU  - KONSTANTINOS POTARIS
AU  - DIMITRIOS DIMITROULIS
AU  - PERIKLIS TOMOS
TI  - Surgical Management of Non-small Cell Lung Cancer with Solitary Hematogenous Metastases
DP  - 2017 May 01
TA  - In Vivo
PG  - 451--454
VI  - 31
IP  - 3
4099  - http://iv.iiarjournals.org/content/31/3/451.short
4100  - http://iv.iiarjournals.org/content/31/3/451.full
SO  - In Vivo2017 May 01; 31
AB  - Background/Aim: The treatment of patients with solitary hematogenous metastases from non-small cell lung cancer (NSCLC) remains controversial, although numerous retrospective studies have reported favorable results for patients offered combined surgical therapy. Our aim was to determine the role of surgical resection in the management of NSCLC with solitary extrapulmonary metastases and to investigate for possible prognostic factors. Patients and Methods: Between January 2004 and December 2012, 12 patients with NSCLC, from two Institutions, underwent metastasectomy for their solitary metastatic lesion. Sites of metastases included brain (n=3), adrenal gland (n=6), thoracic wall (n=2) and diaphragm (n=1). All patients had undergone pulmonary resections for their primary NSCLC. Results: Median survival for the entire cohort was 24.1 months, whereas 1- and 5-year survival rates were 73% and 39%, respectively. Patients with stage III intrathoracic disease had significantly worse survival than those with lower tumor stage. A tendency for adenocarcinomatous histology to positively affect survival was recognized, although it was proven not to be statistically significant. Conclusion: Despite the retrospective nature of our study and the small cohort size, it is emerging that combined surgical resection might offer patients with NSCLC with solitary hematogenous metastases a survival benefit. Limited intrathoracic disease and adenocarcinomatous histology might be associated with better outcomes.